Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL18249519 | 1.00 | LMNA (0.67) | LMNABLMPTPN1ALDH1A1CYP3A4 | |
| Glycerin SCHEMBL6580804 | 0.86 | LMNA (0.48) | LMNABLMPTPN1ALDH1A1CYP3A4 | |
| SCHEMBL11574108 | 0.85 | LMNA (0.74) | LMNABLMPTPN1CYP3A4MEN1 | |
| SCHEMBL9465379 | 0.84 | LMNA (0.50) | LMNABLMPTPN1ALDH1A1CYP3A4 | |
| SCHEMBL9756758 | 0.82 | LMNA (0.68) | LMNABLMPTPN1CYP3A4MEN1 | |
| SCHEMBL9466533 | 0.82 | LMNA (0.68) | LMNABLMPTPN1CYP3A4MEN1 | |
| SCHEMBL31558046 | 0.82 | THRB (0.48) | LMNABLMPTPN1ALDH1A1CYP3A4 | |
| Squalane SCHEMBL5946132 | 0.82 | LMNA (0.78) | LMNABLMPTPN1ALDH1A1CYP3A4 | |
| SCHEMBL11363905 | 0.82 | LMNA (0.68) | LMNABLMPTPN1CYP3A4MEN1 | |
| Squalane SCHEMBL4987345 | 0.82 | LMNA (0.78) | LMNABLMPTPN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042536-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2024-07-23 | — | — | US | disclosed |
| EP-4355361-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | Aurora Vaccines, Inc. (CA) | 2024-04-24 | — | — | EP | disclosed |
| US-20240058438-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | Helmholtz Center for Infection Research (DE) | 2024-02-22 | — | — | US | disclosed |
| WO-2022261758-A9 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | AURORA VACCINES, INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| US-11576968-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-02-14 | — | — | US | disclosed |
| WO-2022261758-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | AURORA VACCINES, INC. (CA) | 2022-12-22 | — | — | WO | disclosed |
| US-20210170018-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20210052721-A1 | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-02-25 | — | — | US | disclosed |
| EP-3765075-A1 | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | The Governors of the University of Alberta (CA) | 2021-01-20 | — | — | EP | disclosed |
| US-10881726-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-01-05 | — | — | US | disclosed |
| WO-2019173925-A1 | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-09-19 | — | — | WO | disclosed |
| EP-3525817-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS COMPRISING AS AN ADJUVANT A CYCLIC DINUCLEOTIDE OR AN ARCHAEOSOME AND METHODS OF USE THEREOF | The Governors of the University of Alberta (CA) | 2019-08-21 | — | — | EP | disclosed |
| US-20190231867-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-08-01 | — | — | US | disclosed |
| WO-2018068132-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS COMPRISING AS AN ADJUVANT A CYCLIC DINUCLEOTIDE OR AN ARCHAEOSOME AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-04-19 | — | — | WO | disclosed |
| EP-1670436-B1 | COMPOSITION COMPRISING ETHER LIPID | CAMURUS AB (SE) | 2013-11-20 | — | — | EP | disclosed |
| US-20070231374-A1 | Composition Comprising Ether Lipid | CAMURUS AB (SE) | 2007-10-04 | — | — | US | disclosed |
| EP-1670436-A2 | COMPOSITION COMPRISING ETHER LIPID | CAMURUS AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005027976-A2 | COMPOSITION COMPRISING ETHER LIPID | CAMURUS AB (SE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042536-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | HAVCR2, CD74, DNAJC10 | LMNA 4357/4885BLM 811/4885PTPN1 426/4885 |
| US-20210170018-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, CD74, DNAJC10 | LMNA 4357/4885BLM 811/4885PTPN1 426/4885 |
| US-10881726-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | HAVCR2, CD74, DNAJC10 | LMNA 4357/4885BLM 811/4885PTPN1 426/4885 |
| US-20190231867-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, CD74, DNAJC10 | LMNA 4357/4885BLM 811/4885PTPN1 426/4885 |
| US-20240058438-A1 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, CD74, DNAJC10 | LMNA 4357/4885BLM 811/4885PTPN1 426/4885 |
| US-11576968-B2 | Hepatitis C virus immunogenic compositions and methods of use thereof | HAVCR2, CD74, DNAJC10 | LMNA 4357/4885BLM 811/4885PTPN1 426/4885 |
| US-20070231374-A1 | Composition Comprising Ether Lipid | ABHD16A, PHOSPHO1, LIPA | LMNA 1117/4885BLM 2316/4885PTPN1 265/4885 |
| US-20210052721-A1 | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | HLA-DRB1, CD4, HLA-C | LMNA 4147/4885BLM 3232/4885PTPN1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.